Marco Prinz
Principal Investigator
Institute of Neuropathology
Medical Center University of Freiburg
Breisacher Str. 64
79106 Freiburg
- +49 761 270-51060
- marco.prinz@uniklinik-freiburg.de
- Homepage
Current position
Academic training
| 1990 - 1996 | Medical study at Humboldt University (Charité) of Berlin |
Advanced academic qualifications
| 2004 | Habilitation in Neuropathology, Georg-August-University Göttingen |
| 1997 | Dissertation in Medicine, Humboldt-University, Medical Hospital (Charité) Berlin |
Postgraduate positions
| Since 2008 | W3 Professor, Medical Director of the Institute of Neuropathology, Medical Center University of Freiburg |
| 2004 | Lecturer (“Habilitation”) and consultant (“Oberarzt”) in Neuropathology |
| 2002 - 2008 | Group leader at the Institute of Neuropathology, University of Göttingen |
| 2001 - 2002 | Senior research postdoc at the Institute of Neuropathology, University of Zurich, Switzerland |
| 1999 - 2000 | Postdoctoral fellow (DFG fellowship) at the Institute of Neuropathology, University of Zurich, Switzerland |
| 1997 - 1998 | Postdoc position in Cellular Neurosciences at Max-Delbrück-Center (MDC) Berlin |
Miscellaneous (Honors, Awards)
| 2021 | Novo Nordisk Prize |
| 2021 | Member of the National Academy of Sciences Leopoldina |
| 2020 | Gottfried-Wilhelm-Leibniz-Prize |
| 2018 - 2020 | annually, Highly Cited Researcher, Web of Science |
| 2018 | Ernst Jung Prize for Medicine |
| 2015 | Reinhart Kosellek Research Project |
| 2014 | Sobek Prize |
| 2014 - 2019 | annually, Writer Prize (Cluster of Excellence BIOSS) |
| 2007 | Hans Georg Queckenstedt Prize (DMSG) |
| 2006 | Young Investigator Award, (International Cytokine Society, Vienna) |
| 2005 | Pfizer Research Prize for Medicine of the University of Freiburg |
| 2004 | H.G. Creutzfeldt Science Prize |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Zeiser R, Prinz M. Immune checkpoint inhibitor induced neurocognitive deficits in patients. Brain Commun. 2023 Jun 20;5(3):fcad186. doi: 10.1093/braincomms/fcad186.
Amann L, Masuda T, Prinz M. Mechanisms of myeloid cell entry to the healthy and diseased central nervous system. Nat Immunol. 2023 Mar;24(3):393-407. doi: 10.1038/s41590-022-01415-8. Epub 2023 Feb 9.
Neuwirt E, Magnani G, Ćiković T, Wöhrle S, Fischer L, Kostina A, Flemming S, Fischenich NJ, Saller BS, Gorka O, Renner S, Agarinis C, Parker CN, Boettcher A, Farady CJ, Kesselring R, Berlin C, Backofen R, Rodriguez-Franco M, Kreutz C, Prinz M, Tholen M, Reinheckel T, Ott T, Groß CJ, Jost PJ, Groß O. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis. Sci Signal. 2023 Jan 17;16(768):eabh1083. doi: 10.1126/scisignal.abh1083. Epub 2023 Jan 17.
Aktories P, Petry P, Glatz P, Andrieux G, Oschwald A, Botterer H, Gorka O, Erny D, Boerries M, Henneke P, Groß O, Prinz M, Kierdorf K. An improved organotypic cell culture system to study tissue-resident macrophages ex vivo. Cell Rep Methods. 2022 Jul 26;2(8):100260. doi: 10.1016/j.crmeth.2022.100260.
Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, Del Gaudio F, He L, Paterson N, Nent E, Fernández-Klett F, Yamasaki A, Frosch M, Fliegauf M, Bosch LFP, Ulupinar H, Hagemeyer N, Schreiner D, Dorrier C, Tsuda M, Grothe C, Joutel A, Daneman R, Betsholtz C, Lendahl U, Knobeloch KP, Lämmermann T, Priller J, Kierdorf K, Prinz M. Specification of CNS macrophage subsets occurs postnatally in defined niches. Nature. 2022 Apr;604(7907):740-748. doi: 10.1038/s41586-022-04596-2. Epub 2022 Apr 20. Erratum in: Nature. 2022 Oct;610(7930):E1.
Contact
